PMC:7033706 / 7332-7988 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"199","span":{"begin":321,"end":329},"obj":"Species"},{"id":"200","span":{"begin":402,"end":406},"obj":"Species"},{"id":"201","span":{"begin":423,"end":426},"obj":"Species"},{"id":"202","span":{"begin":443,"end":446},"obj":"Species"},{"id":"203","span":{"begin":507,"end":516},"obj":"Species"},{"id":"204","span":{"begin":192,"end":200},"obj":"Species"},{"id":"205","span":{"begin":104,"end":123},"obj":"Disease"},{"id":"206","span":{"begin":281,"end":300},"obj":"Disease"},{"id":"207","span":{"begin":636,"end":655},"obj":"Disease"}],"attributes":[{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"Tax:694009"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"Tax:11118"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"Tax:11118"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"Tax:11118"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"Tax:2697049"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"Tax:694009"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:C000657245"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"MESH:C000657245"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It may take several months or even years for researching and developing neutralizing antibodies against 2019-nCoV infection. One of the rapid approaches is to evaluate the currently available SARS-CoV neutralizing antibodies with cross-neutralizing and protection activity against 2019-nCoV infection. We have shown that SARS-CoV S-RBD-specific neutralizing mAbs and sera could cross-neutralize bat-SL-CoVs, such as bat-SL-CoV-W1V1 and bat-SL-CoV-SHC014 [13], suggesting that they may also cross-neutralize 2019-nCoV. Once identified, these cross-neutralizing antibodies can be promptly developed for urgent prevention and treatment of 2019-nCoV infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T34","span":{"begin":104,"end":123},"obj":"Disease"},{"id":"T35","span":{"begin":114,"end":123},"obj":"Disease"},{"id":"T36","span":{"begin":192,"end":200},"obj":"Disease"},{"id":"T37","span":{"begin":281,"end":300},"obj":"Disease"},{"id":"T38","span":{"begin":291,"end":300},"obj":"Disease"},{"id":"T39","span":{"begin":321,"end":329},"obj":"Disease"},{"id":"T40","span":{"begin":636,"end":655},"obj":"Disease"},{"id":"T41","span":{"begin":646,"end":655},"obj":"Disease"}],"attributes":[{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"It may take several months or even years for researching and developing neutralizing antibodies against 2019-nCoV infection. One of the rapid approaches is to evaluate the currently available SARS-CoV neutralizing antibodies with cross-neutralizing and protection activity against 2019-nCoV infection. We have shown that SARS-CoV S-RBD-specific neutralizing mAbs and sera could cross-neutralize bat-SL-CoVs, such as bat-SL-CoV-W1V1 and bat-SL-CoV-SHC014 [13], suggesting that they may also cross-neutralize 2019-nCoV. Once identified, these cross-neutralizing antibodies can be promptly developed for urgent prevention and treatment of 2019-nCoV infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T95","span":{"begin":264,"end":272},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T96","span":{"begin":395,"end":398},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T97","span":{"begin":408,"end":419},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T98","span":{"begin":436,"end":439},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"}],"text":"It may take several months or even years for researching and developing neutralizing antibodies against 2019-nCoV infection. One of the rapid approaches is to evaluate the currently available SARS-CoV neutralizing antibodies with cross-neutralizing and protection activity against 2019-nCoV infection. We have shown that SARS-CoV S-RBD-specific neutralizing mAbs and sera could cross-neutralize bat-SL-CoVs, such as bat-SL-CoV-W1V1 and bat-SL-CoV-SHC014 [13], suggesting that they may also cross-neutralize 2019-nCoV. Once identified, these cross-neutralizing antibodies can be promptly developed for urgent prevention and treatment of 2019-nCoV infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52","span":{"begin":399,"end":401},"obj":"Chemical"},{"id":"T53","span":{"begin":420,"end":422},"obj":"Chemical"},{"id":"T54","span":{"begin":440,"end":442},"obj":"Chemical"}],"attributes":[{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"}],"text":"It may take several months or even years for researching and developing neutralizing antibodies against 2019-nCoV infection. One of the rapid approaches is to evaluate the currently available SARS-CoV neutralizing antibodies with cross-neutralizing and protection activity against 2019-nCoV infection. We have shown that SARS-CoV S-RBD-specific neutralizing mAbs and sera could cross-neutralize bat-SL-CoVs, such as bat-SL-CoV-W1V1 and bat-SL-CoV-SHC014 [13], suggesting that they may also cross-neutralize 2019-nCoV. Once identified, these cross-neutralizing antibodies can be promptly developed for urgent prevention and treatment of 2019-nCoV infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T40","span":{"begin":0,"end":124},"obj":"Sentence"},{"id":"T41","span":{"begin":125,"end":301},"obj":"Sentence"},{"id":"T42","span":{"begin":302,"end":517},"obj":"Sentence"},{"id":"T43","span":{"begin":518,"end":656},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It may take several months or even years for researching and developing neutralizing antibodies against 2019-nCoV infection. One of the rapid approaches is to evaluate the currently available SARS-CoV neutralizing antibodies with cross-neutralizing and protection activity against 2019-nCoV infection. We have shown that SARS-CoV S-RBD-specific neutralizing mAbs and sera could cross-neutralize bat-SL-CoVs, such as bat-SL-CoV-W1V1 and bat-SL-CoV-SHC014 [13], suggesting that they may also cross-neutralize 2019-nCoV. Once identified, these cross-neutralizing antibodies can be promptly developed for urgent prevention and treatment of 2019-nCoV infection."}